EVIDENCE LIBRARY
SGCE Myoclonus–Dystonia Case Reported Clonazepam Nonresponse Despite Preserved Development
A genetic movement-disorder case separated symptom persistence from broader developmental outcome. Lack of medication response did not imply progressive global impairment.
A genetic movement-disorder case separated symptom persistence from broader developmental outcome. Lack of medication response did not imply progressive global impairment.
The clinical findings
A child had persistent myoclonus beginning in infancy and later mild dystonia. Imaging, EEG, and metabolic workup were unrevealing, while genetic testing identified a pathogenic SGCE variant.
Several medicines, including clonazepam, did not improve symptoms. Motor and cognitive development remained broadly average, although behavioral and attentional issues later emerged.
One case does not establish a response rate
The report cannot estimate clonazepam efficacy for all SGCE-related disease or show that every treatment failure has the same explanation. Genetic diagnosis and longitudinal observation supplied evidence different from medication response.
A forensic account should distinguish myoclonus from epileptic seizures, symptom severity from function, and baseline traits from later changes. Persistent movements despite a benzodiazepine do not establish nonadherence or exclude a genetic disorder. Continued follow-up remained relevant even when early development was favorable.
Source paper
Original analysis of the supplied journal article, identified as PMC12851603.